Evidence map›Paper›PMID 34714485›Full record

ArticleMolecular biology reports2022

Anticancer activity of N-heteroaryl acetic acid salts against breast cancer; in silico and in vitro investigation.

Samaneh Zolghadri, Ali Ghanbariasad, Fatemeh Fallahian, Mahdie Rahban, Mahsa Kalavani, Enayatollah Bahman Jahromi, Azizeh Asadzadeh, Maliheh Hajiani

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Samaneh ZolghadriDepartment of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
Ali GhanbariasadNoncommunicable Diseases, Research Center, Fasa University of Medical Science, Fasa, Iran.
Fatemeh FallahianDepartment of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
Mahdie RahbanInstitute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Mahsa KalavaniDepartment of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
Enayatollah Bahman JahromiDepartment of Biology, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
Azizeh AsadzadehDepartment of Biology, Faculty of Science, Nour-Danesh Institute of Higher Education, Mymeh, Isfahan, Iran.
Maliheh HajianiSchool of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran. hajiani_malihe@yahoo.com.ORCID http://orcid.org/0000-0002-1333-2317
Islamic Azad University, Jahrom Branch · IRDanesh-e-Tandorosti Iranian Institute of Higher Health · IRFasa University of Medical Sciences · IRJahrom University · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe present research was performed to assess N-heteroaryl acetic acid salts' anticancer activity against the breast cancer cell in order to introduce new inhibitory agents for histone deacetylase. METHODS AND

resultsA molecular docking simulation was performed to design the rational novel compounds. Afterward, the best compounds were selected for synthesis. The cytotoxic effects and mechanism of action have been studied via (Methyl Thiazol-Tetrazolium) MTT assay. Flow cytometry and gene expression analyses were performed to introduce an effective acetic acid derivative as an anticancer agent. Molecular docking simulations demonstrated that all compounds have the best interaction with histone deacetylase. The fold changes of Bcl-2, Bak, Bim, Caspase-3, and Caspase-8 gene expressions were investigated and compared with reference gene using real-time PCR. The cytotoxic studies showed the best anticancer activity of 4-benzyl-1-(carboxymethyl) pyridinium bromide (compound 2) with a low IC

conclusionThese results suggest that compound 2 with the benzyl ring could be an effective anticancer compound for further investigation in breast cancer treatment.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCell MovementCell ProliferationCell SurvivalFemaleGene Expression Regulation, EnzymologicHistone Deacetylase InhibitorsHistone DeacetylasesHumansInhibitory Concentration 50MCF-7 CellsModels, MolecularMolecular Docking SimulationPyridinium CompoundsStructure-Activity RelationshipAntineoplastic AgentsHistone Deacetylase InhibitorsHistone DeacetylasesPyridinium CompoundsAnticancerApoptosisBreast cancerFlow cytometryHDAC inhibitorReal-time PCR

Identifiers

PMID34714485
OpenAlexW3209749680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.